Table 1. Cases included in current study.

Case	Age	Final MMSE score	ApoE alleles	PMI (hours)	Braak NFTs stage	CERAD plaque stage	Diffuse plaques	Neuritic plaques	NFTs	RIN-GM	RIN-WM
1	85	28	3/3	2.50	0	No	0	0	0	5.7	3.4
2	79	29	3/3	1.75	I	No	0	0	0	6.0	6.1
3	84	29	3/3	2.50	I	No	0	0	0	6.6	6.6
4	92	29	3/3	3.00	II	No	0	0	0	7.3	6.9
5	86	26	–	3.25	III	B	5	5.8	0	7.2	7.9
6	92	30	2/3	3.25	III	B	36.6	8.2	1.2	7.1	6.6
7-D	84	13.5	3/3	2.60	IV	C	50	12.8	0	2.3	2.3
8	88	28	3/3	3.00	III	C	41	16.4	0	5.1	5.5
9	99	16	3/4	2.10	V	C	50	20	23.6	5.9	6.2
10	91	13	3/3	3.00	V	C	46.2	35	42.6	5.5	6.1

List of cases with data about clinical, neuropathological, and RNA quality parameters. The focus of this study comprises the spectrum of disease from “no pathology” to “early AD” pathology. All ten individuals were Caucasian females. Final MMSE examinations were administered an average 10.9 months before death (median 7.2 months before death). Diffuse plaques, neuritic plaques, and neurofibrillary tangles (NFTs) were counted on adjacent tissue sections of superior and mid-temporal cortical tissue as described in “Methods”. Cases are arranged according to density of neuritic plaques in these tissues. Note that case #7-D has low RNA integrity numbers (RIN), which indicates substantial RNA degradation. White matter of case 1 (italic values) has marginal RNA quality. “Plaque stage” refers to CERAD scores, with B indicating moderate density of neuritic plaques and C indicating high density of neuritic plaques